Threading a catheter from an artery in the groin up into the blood vessels of the brain is one of the most delicate procedures in medicine. It's how doctors treat strokes and brain aneurysms, and it requires a neurointerventionalist with years of specialized training — a specialty so scarce that where you have your stroke can determine whether you get that care in time. Houston's XCath is building a robot to do the threading, and it just raised $30 million to keep going.
The Milestone That Preceded the Money
In late 2025, XCath announced the first-in-human use of its endovascular robotic (EVR) system, treating three patients with complex brain aneurysms. With those procedures, XCath's system became the only endovascular robot in development to achieve intracranial navigation — meaning it didn't just operate in the large vessels of the body, but successfully navigated into the delicate vasculature inside the skull and performed neurointerventional treatment there.
That distinction matters. Robotic catheter systems have existed for cardiac work, where vessels are larger and more forgiving. The brain is the hard case: vessels are small, tortuous, and fragile, and the consequences of a wrong move are severe. Getting a robot to navigate there in a live patient is a genuine technical milestone.
The Funding — and Who's Behind It
In March 2026, XCath closed a $30 million Series C led by Crescent Enterprises and by Dr. Fred Moll, bringing total funding to roughly $92 million. Moll's participation is the detail worth pausing on: he founded Intuitive Surgical, the company behind the da Vinci system that effectively created the surgical-robotics industry. When the person who built the category's defining company backs an early-stage robot, it's a meaningful signal about the technology's plausibility.
XCath was founded in 2017 and is led by Nicholas Drysdale and Eduardo Fonseca. It maintains campuses in Houston — next to the world's largest medical complex — and in Pangyo, South Korea, a major technology hub. The company is also building on NVIDIA's Isaac for Healthcare platform for its next generation of interventional robotics, tying it into the same robotics-AI stack now showing up across industrial robotics.
The Real Prize: Telerobotic Stroke Care
The most consequential thing about endovascular robotics isn't precision — it's distance. In 2024 XCath performed what was billed as the world's first public telerobotic mechanical thrombectomy demonstration, at Abu Dhabi Global Healthcare Week. A thrombectomy physically removes the clot causing a stroke, and it is extraordinarily time-sensitive: the longer the brain goes without blood flow, the more of it is lost.
The problem is that neurointerventionalists cluster in major medical centers. A patient having a stroke in a rural hospital may be hours from someone qualified to perform the procedure — hours the brain doesn't have. If a specialist in Houston can operate a robot in a hospital hundreds of miles away, the geography of who receives timely stroke care changes fundamentally. That's the ambition, and it's why XCath frames its goal as standardizing treatment so that consistent outcomes are achievable across a much wider field of physicians.
Why It's a Houston Company
XCath's Houston base is not incidental. Building a surgical robot requires constant iteration with the clinicians who will use it, and the Texas Medical Center puts an enormous concentration of interventional specialists and high-acuity cases within a few miles. It's the same dynamic driving EndoQuest Robotics, the Houston company pursuing incisionless endoluminal surgery, and it's what makes the region a genuine center for building surgical robots rather than only using them.
Between XCath in the brain's vasculature, EndoQuest in the GI tract, and the deep robotic-surgery practice across TMC institutions, Houston's medical robotics scene is developing real depth. For more, see our guide to surgical robotics at the Texas Medical Center or browse the company directory.
Based on XCath announcements and medical-technology trade coverage of its Series C and first-in-human procedures.